POS0078 CROSS-SECTIONAL ANALYSIS OF INTERFERON SIGNATURE IN PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS

Background: the role of interferon pathways in pathogenesis systemic lupus erythematosus (SLE) has been proven over past years. Existing data suggest that score (IFN I score) may serve as a useful marker disease activity and patient clinical characteristics. Objectives: to compare characteristics pediatric SLE patients with high normal IFN score. Methods: 40 (33 girls, 7 boys) under 18 years old were included cross-sectional study. In all cases diagnosis was made using Systemic Lupus International Collaborating Clinics (SLICC) classification criteria. The on manifestations, by SLEDAI ECLAM, laboratory findings onset at moment signature assessment evaluated. Interferon assessed real-time PCR quantitation 5 I-regulated transcripts; median expression ≥2 considered threshold. divided into 2 groups depending level score: (group1, n=31) (group2, n=9). Results: mean age 12 (9.5; 14.0) most common symptoms skin lesions (85%), arthritis (67.5%), fever (55%), mucosa (45%), CNS (37.5%) kidney (30%) involvement. Anemia, leukopenia thrombocytopenia observed 62.5%, 27.5% 50% cases, while 87.5% 70% had ANA positivity dsDNA antibodies onset. comparison between increased I-signature is presented Table 1. Parameters Group 1 (High IFN-s) (Normal p-value Girls, n (%) 25 (80.7) 8 (88.9) 0.567 age, 12.0(10.0; 11.0 (9.0; 13.0) 0.353 Time IFN-signature study, months from 18.3 (7.0; 26.5) 0.97 (0.87;1.73) 0.987 Skin involvement, (38.7) 4 (44.4) 0.837 n(%) (25.8) (11.1) Arthritis, 11 (35.5) (22.2) 0.455 9 (29.0) (22.20 0.687 Leucopenia, 0.274 ANA-positivity, 27 (87.1) (55.6) 0.037 anti antibodies, 0.361 Rheumatoid factor, 0 (0.0) 0.036 Hypocomplementemia, 18/28 (64.3) 2/6 (33.3) 0.162 Ferritin level, mkg/l 112.0 (39.0; 271.0) 21.0 (5.3; 23.7) 0.0008 Hematuria, 10 (32.3) 0.049 Proteinuria, SELENA-SLEDAI, points (2;15) (0; 4) 0.073 3.0 (1.0; 6.0) 1.0 (0.0; 1.5) 0.048 Treatment Rituximab or Cyclophosphamide, 22 (71.0) 3 0.040 GCS dose 0,2 mg/kg achievement for 6 months, 9/21 (42.9) 5/6 (83.3) 0.080 Conclusion: correlated RF-positivity, ferritinemia, proteinuria hematuria. Patients received more aggressive treatment needed longer glucocorticosteroid (GCS) treatment. More meticulous dynamic evaluation clarify its predictive prognostic marker. Acknowledgements: This work supported RSF grant № 20-45-01005. Disclosure Interests: None declared.